Myeloid Therapeutics and Prime Medicine have signed an exclusive option and research collaboration agreement to advance the development of Myeloid Therapeutics’ retrotransposon-mediated gene insertion technology, RetroT.
The ribonucleic acid (RNA) based technology has applications in gene editing and delivery and can be used alongside Prime Editing to simplify the delivery of ex vivo and in vivo cell therapies.
RetroT delivers genetic sequences and integration enzymes in one mRNA strand and enables the delivery of gene-sized pieces of DNA into the genome.
It also has the potential to significantly expand the type and scope of genetic errors that can be reversed in situ.
Under the partnership deal, the companies will work together to optimise the technology for use in multiple cell types and expand its programmability.
They will also aim to increase its efficiency to allow it to be directed to prespecified target sites within the genome.
Myeloid CEO Daniel Getts said: “At Myeloid, we are pleased to have built one of the deepest RNA-based technology platforms focused on multiple therapeutic modalities, including our newest technology announced today for gene editing, RetroT.
“We are excited to be working with Prime, a preeminent gene editing company, to continue pushing the boundaries of what mRNA can do, including gene delivery.”
Prime Medicine CEO Keith Gottesdeiner said: “We look forward to partnering with the extremely talented team at Myeloid – including many experts in retrotransposon biology – to advance this novel technology, with the goal of expanding the applicability of Prime Editing to more broadly address human diseases.”
Under the terms agreed, the company received a $45m upfront payment and is also eligible for significant milestone and option exercise payments, as well as royalties based on sales.
The deal also includes the exclusive option for Prime Medicine to gain control of the intellectual property estate to expand on its current technology platform.